教育背景

2018.01－2020.04     美国UT.MD安德森癌症中心   博士后

2014.09－2017.07    复旦大学        理学博士

2011.09－2012.07    浙江大学        博士在读

2008.09－2011.07    哈尔滨医科大学   理学硕士

工作经历

2020.05－今       上海中医药大学中药研究所 研究员，博士生导师

2018.01－2020.04   美国UT.MD安德森癌症中心   博士后

2012.07－2017.09   江南大学附属医院助理研究员

以满足临床未满足之需求为研究目标，基于消化道肿瘤大样本多组学分析进行药物靶点开发，阐明其分子机制，为抗肿瘤药物靶向性研究奠定基础。积极探索基于非编码RNA开展药物作用靶点发现研究，并基于相应的RNA分子靶点进行抗肿瘤新药研究。

个人荣誉

2020年度上海市浦江学者；第十二批上海市领军人才（海外）青年项目。

获奖情况

江苏省新医学技术引进奖一等奖1项（2016，名列第3位）

15. M Chen, C Li, J Zhang, X Cui, W Tian, P Liao, Q Wang, J Sun, L Luo, H  Wu, Y Li. Cancer and Atrial Fibrillation Comorbidities Among 25 Million Citizens in Shanghai, China: Medical Insurance Database Study. JMIR Public health and surveillance.2023.

14. T Feng, Y Li, F Ma, E Wu, Z Cheng, S Zhou,Z Wang, L Yang, XSun, J Zhang. Ft1 inhibits colorectal cancer growth by increasing CD8⁺ T cell proportion in tumor-bearing mice through the USP9X signaling pathway. Chinese Journal of Natural Medicines.2023.

13. A Xiong, J Zhang, Yan Chen, Yi Zhang, Fan Yang. Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM. EBioMedicine. 2022.

12.J Zhang, T Pan, W Zhou, Y Zhang, G Xu, Q Xu, S Li, Y Gao, Z Wang, J Xu, Yongsheng Li. Long noncoding RNA LINC01132 enhances immunosuppression and therapy resistance via NRF1/DPP4 axis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2022.

11.J Zhang, S Li, J Zhang, W Zhang, J Jiang, H Wu, E Wu, Y Feng, LYang, Z Li. Docetaxel resistance-derived LINC01085 contributes to the immunotherapy of hormone-independent prostate cancer by activating the STING/MAVS signaling pathway. Cancer Letters. 2022.

10. J Zhao, J Zhang, Q Liu, Y Wang, Y Jin, Y Yang, C Ni, L Zhang. Hongjingtian injection protects against myocardial ischemia reperfusion-induced apoptosis by blocking ROS induced autophagic- flux. Biomed Pharmacother. 2021.

 9. Yang Jiao^#, Jialiang Zhou^#, Mingxu Song, Ling Zhang, Jiayan Zhou*, Jiwei Zhang*. Long non-coding RNA TDRKH-AS1 promotes colorectal cancer cell proliferation and invasion through the β-catenin activated Wnt signaling pathway. Frontiers in Oncology. 2020.

 8. J Xu^#*, T Shao^#, M Song^#, Y Xie, J Zhou, J Yin, Na Ding, H Zou, Y Li*, J Zhang*. MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer. Molecular Cancer.2020.

 7. J Zhang^#*, S Li^#, L Zhang^#, J Xu, M Song, T Shao, Z Huang, Y Li. Integrative analyses reveal EIF2S2-LINC01600-MYC axis suppresses the regulation of FHIT enhancer to Wnt signaling pathway in gastrointestinal cancer. Molecular Therapy. 2020.

 6. S Shen^#, J Wang^#, Y Shao, Y Tao, M Li, Y Wang, X Ni, T Suo, H Liu*, Han Liu*, J Zhang*. The LINC01714 acts as a tumor suppressor in cholangiocarcinoma by interacting with FOXO3. Molecular Therapy-Nucleic Acids,2020.

 5. Z Bian^#, J Zhang^#, M Li, Y Feng, X Wang, J Zhang, S Yao, G Jin, J Du,Z Huang*. LncRNA-FEZF1-AS1 promotes tumor proliferation and metastasis in colorectal cancer by regulating PKM2 signaling. Clinical Cancer Research. 2018.

 4. J Zhang^#, Z Li^#, Liu L^#, Wang Q, Li S, Chen D, Hu Z, Yu T, Ding J, Li J, Yao M, Huang S, Zhao Y*, He X*. Long Noncoding RNA TSLNC8 Is a Tumor Suppressor that Inactivates the IL6/STAT3 Signaling Pathway. Hepatology. 2018. 

 3. Li Z^#, J Zhang^#, L L#, W Q, Li S, Chen D, Hu Z, Yu T, Ding J, Li J, Yao M, Huang S, Zhao Y*, He X*. The LINC01138 drives malignancies via activating arginine methyltransferase 5 in hepatocellular carcinoma. Nature Communications. 2018. 

 2. S Li, J Zhang, S Huang, X He*.  Genome-wide analysis reveals that exon methylation facilitates its selective usage in the human transcriptome. Briefings in Bioinformatics. 2017. 

 1. J Zhang^#, Z Bian^#, J Zhou, M Song, Z Liu, Y Feng, Z Li, B Zhang, Y Yin, Z Huang*. MicroRNA-638 inhibits cell proliferation by targeting phospholipase D1 in human gastric carcinoma. Protein & cell. 2016. 

无

1：长链非编码RNA—MIR22HG通过调控SMAD2抑制结直肠癌生长与转移的分子机制研究（项目批准号：81602033）、国家自然科学基金、17万元、起止日期：2017.01-2019.12,、结题、主持

2：EIF2S2通过STAT3/CD155/TIGIT轴促进结直肠癌免疫逃逸的机制研究（项目批准号：20PJ1413000）、上海市浦江人才、30万元、起止日期：2020.10-2022.9,、结题、主持

3：RNA结合蛋白EIF2S2通过STAT3/CD155轴促进结直肠癌免疫逃逸分子机制研究（项目批准号：82173106）、国家自然科学基金面上项目、55万元、起止日期：2022.01-2025.12,、在研、主持；

4：基于质量源于设计理念的“同方异制”生脉、复方丹参方质量评价新策略（项目批准号：82130115）、国家自然科学基金重点项目、290万元、起止日期：2022.01-2026.12,、骨干参与。

兼任Frontiers in Pharmacology 客座主编，《中医药文化》青年编委。